Medicinova Inc (NASDAQ:MNOV)
| Market Cap | 68.91M-6.7% |
| Revenue (ttm) | 920.48K+583.9% |
| Net Income | -10.75M+9.0% |
| EPS | -0.22+9.8% |
| Shares Out | 49.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 29,680 |
| Open | 1.40 |
| Previous Close | 1.40 |
| Day's Range | 1.38 - 1.42 |
| 52-Week Range | 1.22 - 3.90 |
| Beta | 0.61 |
| Analysts | Buy |
| Price Target | 6.00(+328.57%) |
| Earnings Date | Nov 12, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About MNOV
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Next catalysts
- Nov 12, 2026Earnings report
Ask Barron about MNOV
$MNOV stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in MNOV holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by MNOV's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
MNOV Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New MNOV patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to MNOV from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in MNOV
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $4.43M |
| VXFVanguard Extended Market ETF | $991.52K |
| IWCiShares Micro-Cap ETF | $202.06K |
| BUSMEA Series Trust - EA Bridgeway Ultra-Small Company Market ETF | $70.00K |
Estimated from each fund’s disclosed top holdings × AUM
MNOV Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from MNOV’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
Biotech: 99 sector peers carry a ranked score; this one has no qualifying buying in the window · sector average 59.6
What’s Behind the Score
Recent Insider Activity
Insider Score Trend Over Time
+0.0 since Sep 30Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.